Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.

  • Authors: Y Nakamoto, S Kaneko, S W Buttner, E Matsushita, K Kobayashi
  • View Affiliations

  • Published online on: Thursday, July 1, 1999
  • Pages: 733-742
  • DOI: 10.3892/or.6.4.733

Abstract

We monitored apoptosis of peripheral blood lymphocytes (PBL) obtained from patients with various degrees of chronic viral hepatitis, including hepatocellular carcinoma (HCC), in vitro and quantitated the serum levels of soluble Fas ligand (FasL) by ELISA. There was no difference in mean percent PBL mortality. However, in HCC patients, the variance was significantly high (P<0.05), and, unexpectedly, a negative association was found between the PBL mortality and the serum soluble FasL levels (P=0.035). These results suggest the inhibitory effect of serum soluble FasL on apoptosis of PBL, which may explain the induction of immunological abnormalities with the development of HCC.
Journal Cover

July 1999
Volume 6 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakamoto, Y., Kaneko, S., Buttner, S., Matsushita, E., & Kobayashi, K. (1999). Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.. Oncology Reports, 6(4), 733-742.
MLA
Nakamoto, Kaneko, Buttner, Matsushita, and K Kobayashi. "Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.." Oncology Reports Oncology Reports 6.4 (1999): 733-742.
Chicago
Nakamoto, Kaneko, Buttner, Matsushita, and K Kobayashi. "Inhibition of peripheral blood lymphocyte apoptosis by soluble fas ligand in patients with hepatocellular carcinoma.." Oncology Reports Oncology Reports 6 no. 4 (1999): 733-742.